ARQL - ArQule, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.57
-0.03 (-0.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.60
Open10.61
Bid10.58 x 2900
Ask10.50 x 2200
Day's Range10.44 - 10.76
52 Week Range2.23 - 12.22
Volume1,197,090
Avg. Volume3,298,738
Market Cap1.271B
Beta (3Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire23 days ago

    ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    ArQule, Inc. (ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the public offering price of $9.75 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by ArQule to 10,637,500 shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by ArQule, to approximately $103.7 million. SVB Leerink and RBC Capital Markets acted as joint bookrunning managers for the offering.

  • Business Wire25 days ago

    ArQule Announces Pricing of $90 Million Public Offering of Common Stock

    ArQule, Inc. (ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1,387,500 shares of its common stock. The gross proceeds to ArQule from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $90.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by ArQule.

  • Business Wire26 days ago

    ArQule Announces Commencement of Proposed Public Offering of Common Stock

    ArQule, Inc. (ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by ArQule.

  • Business Wirelast month

    ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019

    ArQule, Inc. (ARQL) today announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.m. ET at the The Mandarin Oriental New York, New York. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wirelast month

    ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference

    ArQule, Inc. (ARQL) today announced preliminary results from the company’s phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference in Gothenburg, Sweden.

  • Business Wirelast month

    ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting

    ArQule, Inc. (ARQL) today announced preliminary results from the Company’s phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 2019 European Hematology Association (EHA) Annual Meeting in Amsterdam, the Netherlands.

  • Business Wirelast month

    ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference

    Presentation highlights preliminary results from phase 1/2 study of miransertib in patients with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome

  • Business Wirelast month

    ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)

    Presentation highlights phase 1 dose escalation study in patients with relapsed or refractory B-cell lymphoid malignancies

  • Business Wire2 months ago

    ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019

    ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Jefferies 2019 Healthcare Conference on June 6, 2019 at 11:30 a.m. ET at the Grand Hyatt in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wire2 months ago

    ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

    ArQule, Inc. (ARQL) today announced that Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 at 9:30 a.m. PT at the Beverly Hilton in Beverly Hills, CA. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wire2 months ago

    ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019

    ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 at 3:35 p.m. ET at the InterContinental New York Barclay in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.

  • Business Wire2 months ago

    ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019

    ArQule, Inc. (ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019 at 3:15 p.m. PT at the Encore Hotel in Las Vegas, NV. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wire3 months ago

    ArQule Reports First Quarter 2019 Financial Results

    Conference call scheduled today at 9:00 a.m. ET

  • Business Wire3 months ago

    Sinovant Sciences Announces Approval of Derazantinib’s Clinical Trial Application by the China National Medical Products Administration

    ArQule, Inc.’s (ARQL) partner, Sinovant Sciences, announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration (NMPA), enabling the initiation of a registrational clinical trial in patients with second-line intrahepatic cholangiocarcinoma (iCCA) in the second half of 2019. “This is an important step forward for derazantinib in China, where the unmet need in iCCA is particularly acute,” said Peter Lawrence, President and COO of ArQule.

  • Business Wire3 months ago

    ArQule to Report First Quarter 2019 Financial Results on May 1, 2019

    ArQule, Inc. (ARQL) today announced it will report financial results for the first quarter of 2019 before the market opens on Wednesday, May 1, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wire4 months ago

    ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019

    ArQule, Inc. (ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 18th Annual Needham Healthcare Conference on April 9, 2019 at 10:00 a.m. ET at the Westin New York Grand Central in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wire4 months ago

    ArQule Announces Management Team Changes

    ArQule, Inc. (ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief Financial Officer and Head of Strategy, effective as of Mr. Weiskopf’s retirement. Dr. Schegerin joined ArQule in May 2018 and most recently served as Senior Vice President, Head of Strategy, Finance and Communication.

  • Business Wire4 months ago

    ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019

    ArQule, Inc. (ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 10:20 a.m. ET at the Westin New York Grand Central in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.

  • Business Wire4 months ago

    ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019

    ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in Dana Point, California.

  • Business Wire4 months ago

    ArQule Reports Fourth Quarter and Full Year 2018 Financial Results

    Conference call scheduled today at 9:00 a.m. ET

  • GlobeNewswire5 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire5 months ago

    ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome

    ArQule, Inc. (ARQL), today announced the publication of clinical pharmacodynamic, safety and efficacy data in patients with Proteus syndrome. The study, published in the American Journal of Human Genetics, and led by the National Institutes of Health (NIH), demonstrated good target engagement, tolerability and reductions in lesion size and pain, especially in children.

  • Business Wire5 months ago

    ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

    ArQule, Inc. (ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wire5 months ago

    ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

    ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019, at 11:30 a.m. ET at the Lotte New York Palace in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.

  • Business Wire6 months ago

    Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer

    ArQule, Inc.’s (ARQL) partner, Basilea Pharmaceutica Ltd. (SIX:BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study in mid-2019. The planned study will assess the safety, tolerability and efficacy of the derazantinib-atezolizumab combination in patients with advanced urothelial cancer and confirmed FGFR genomic aberrations.